Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravesically administered BCG may have antiangiogenic effects on urinary concentrations of basic fibroblast growth factor ( bFGF), vascular endothelial growth factor (VEGF) and interleukin (IL-8)

Next Previous
Trial Profile

Intravesically administered BCG may have antiangiogenic effects on urinary concentrations of basic fibroblast growth factor ( bFGF), vascular endothelial growth factor (VEGF) and interleukin (IL-8)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BCG (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use

Most Recent Events

  • 12 May 2008 New trial record.
  • 22 Apr 2008 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top